What the survey did:
This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs. a combination of bamlanivimab and etesevimab vs placebo modified in day 11 of acute coronavirus viral syndrome 2 in patients with COVID -19 moderately mild.
Authors:
The corresponding author is Daniel M. Skovronsky, MD, Ph.D., of Eli Lilly and Company in Indianapolis.
To get to the embargo review:
Visit our For The Media website at this link
https: /
(doi: 10.1001 / jama.2021.0202)
Editor’s note: The articles cover conflicts of interest and funding / support disclosures. Please see the article for more information, including other authors, author contributions and links, conflicts of interest and financial publications, and funding and support.
###
Media Advisor:
The full article is linked to this news release.
Submit this link to give your readers free access to the full-text article
This link will be live during the embargo
https: /
Disclaimer: AAAS and EurekAlert! they are not responsible for the accuracy of press releases posted to EurekAlert! by sending institutions or for using any information through the EurekAlert system.